Publications

ORIGINAL ARTICLES

  1. Kelley VE, Cotran RS. Mesangial and subepithelial localization of ferritin immune complexes in the mouse glomerulus.  Lab Invest 1972; 27:144-150.
  1. Kelley VE, Cavallo T. An ultrastructural study of the glomerular slit diaphragm in New Zealand Black/White mice.  Lab Invest 1976; 35:213-220.
  1. Kelley VE, Cavallo T. Glomerular permeability: Ultrastructural studies in New Zealand Black/White mice using polyanionic ferritin as a molecular probe.  Lab Invest 1977; 37:265-275.
  1. Kelley VE, Cavallo T. Glomerular permeability:  Transfer of native ferritin in glomeruli with decreased anionic sites.  Lab Invest 1978; 39:547-553.
  1. Kelley VE, Cavallo T.  Urinary Protein excretion in normal mice: Variations with age and sex.  Renal Physiol 1979; 1:235-240.
  1. Kelley VE, Winkelstein A, Izui S. Effect of prostaglandin E on immune complex nephritis in NZBxW mice.  Lab Invest 1979; 41:531-537.
  1. Winkelstein A, Kelley VE. The effects of prostaglandin E1 (PGE1) on lymphocytes.  Blood 1980; 55:437-443.
  1. Kelley VE, Cavallo T. Glomerular permeability:  Altered  anionic sites in NZB/W mice with immune complex nephritis.  Lab Invest 1980; 42:59-63.
  1. Kelley VE, Winkelstein A. Age and sex related glomerulonephritis in the New Zealand White mouse.  Clin Immunol Immunopathol 1980; 16:142-150.
  1. Kelley VE, Winkelstein A. Prostaglandin E1 (PGE1) treatment of acute immune complex glomerulonephritis.  Clin Immunol Immunopathol 1980; 16:316-323.
  1. Winkelstein A, Kelley VE. Effects of prostaglandin on NZB/W lymphocytes.  Clin Immunol Immunopathol 1980; 17:212-218.
  1. Cavallo T, Kelley VE, Granholm NA. Glomerular permeability:  Ultrastructural quantitative studies relating proteinuria to pathologic features in murine lupus nephritis.  Am J Pathol 1980; 101:93-100.
  1. Izui S, Kelley VE, McConahey PJ, Dixon FJ. Selective suppression of retroviral gp 70-anti gp 70 immune complex formation by prostaglandin E1 in murine systemic lupus erythematosus. J Exp Med 1980; 152:1645-1657.
  1. Wing EJ, Koren HS, Fischer DG, Kelley VE. Stimulation of a human macrophage-like cell line (U-937) to inhibit multiplication of an intracellular pathogen.  J Reticuloendo Society 1981; 29:321-328.
  1. Winkelstein A, Kelley VE. Effects of PGE1 on immune models of SLE:  Changes in circulating immune complexes.  Clin Immunol Immunopathol 1981; 20:188-192.
  1. Kelley VE, Winkelstein A, Izui S, Dixon FJ. Prostaglandin E1 inhibits T cell proliferation and renal disease in MRL/l mice.  Clin Immunol  Immunopathol 1981; 21:190-203.
  1. Kelley VE, Wing E. Loss of resistance to listeria injection in autoimmune MRL/lpr mice:  Protection by prostaglandin E1.  Clin Immunol Immunopathol 1982; 23:705-710.
  1. Kelley VE, Roths JB. Increase in macrophage Ia expression in autoimmune mice:  Role of the lpr gene.  J Immunol 1982; 29:923-925.
  1. Kelley VE, Izui S, Halushka PV. Effect of ibuprofen, a fatty acid cyclooxygenase inhibitor, in murine lupus.  Clin Immunol Immunopathol 1982; 25:223-231.
  1. Weill BJ, Heavey AC, Kelley VE, Schur P. Use of nuclear  antigen-coated red cells in hemolytic plaque assays.  J Immunol Methods 1983; 57:327-340.
  1. Eastcott JW, Kelley VE. Preservation of T lymphocyte activity in autoimmune MRL-lpr mice treated with prostaglandin.  Clin Immunol Immunopathol 1983; 29:78-85.
  1. Kelley VE, Izui S. Enriched lipid diet accelerates lupus nephritis in NZBxW mice: Synergistic action of immune complexes and lipid in glomerular injury.  Am J  Pathol 1983;111:288-297.
  1. Kelley VE, Fiers W, Strom TB. Cloned human interferon gamma but not interferon beta or alpha induces expression of HLA-DR determinants by fetal monocytes and myeloid leukemic cell lines.  J Immunol 1984;132:240-245.
  1. Izui S, Kelley VE, Masuda K, Yoshida H, Roths JB, Murphy ED. Induction of multiple autoantibodies in normal strains of mice by a mutant lpr gene. J Immunol 1984; 133:227-233.
  1. Cronin PS, Sing AP, Glimcher L, Kelley VE, Reinisch CL. The isolation and functional characterization of autoimmune clones expressing inappropriate Ia. J Immunol 1984; 133:822-829.
  1. Rudofsky UH, Dilwith RL, Roths JB, Lawrence DA, Kelley VE, Magro AM. Differences in the occurrence of hypertension among (NZBxNZW) F1, MRL-lpr, and BXSB mice with lupus nephritis. Am J Pathol 1984; 116:107-114.
  1. Heagy W, Kelley VE, Strom TB, Mayer K, Shapiro H, Mandel R, Finberg R. Decreased expression of human Class II antigens on monocytes of patients with acquired immune deficiency syndrome.  Increased expression with interferon-gamma.  J Clin Invest 1984; 74:2089-2096.
  1. Kelley VE, Ferretti A, Izui S, Strom TB. A fish oil diet rich in eicosapentanoic acid reduces cyclooxygenase metabolites and suppresses lupus in MRL-lpr mice.  J Immunol 1985; 134:1914-1919.
  1. Ythier AA, Williams JM, Shapiro HM, Kelley VE, Strom TB. The early (18 hour) human mixed lymphocyte reaction: Identification and isolation of activated T cell clones.  Cell Immunol 1985; 91:215-226.
  1. Williams JM, Abbud-Filho M, Kelley VE, Strom TB. Interleukin-2 apparently upregulates its receptor and induces proliferation of various resting mononuclear leukocytes in the absence of antigen.  Cell Immunol 1985; 94:383-393.
  1. Kirkman RL, Barrett LV, Gaulton GN, Kelley VE, Ythier AA, Strom TB. Administration of an anti-interleukin-2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med 1985; 162:358-362.
  1. Kelley VE, Roths JB. Interaction of mutant lpr gene with background strain influences renal disease.  Clin Immunol Immunopathol 1985; 37:220-229.
  1. Williams JM, Dinarello GA, Rosenwasser LF, Kelley VE, Reddish M, Strom TB. Direct evidence that PMA temporarily enters and is released from cellular compartments during superinduction protocol.  Lymphokine Res 1985; 4:275-298.
  1. Kirkman RL, Barrett LV, Gaulton GN, Kelley VE, Kolton WA, Schoen FJ, Ythier AA, Strom TB. The effect of anti-interleukin-2 receptor monoclonal antibody on allograft rejection. Transplantation 1985; 40:719-722.
  1. Maddock EO, Maddock SW, Kelley VE, Strom TB. Rapid sterospecific stimulation of lymphocytic metabolism by interleukin-2.  J Immunol 1985; 135:4004-4008.
  1. Kelley VE, Sneve S, Musinski S. Increased renal thromboxane production in murine lupus nephritis. J Clin Invest 1986; 77:252-259.
  1. Kelley VE, Wilion F, Williams JM. A functional analysis of the T cell defect in MRL-lpr mice.  Cell Immunol 1986; 97:210-219.
  1. Kelley VE. Role of cyclooxygenase metabolites in murine autoimmune renal disease. Transplant Proc 1986; 18;659-661.
  1. Abbud-Filho M, Ransil BJ, Kelley VE, Fiers W, Strom TB. Natural killer cell response to interferons.  Clin Immunol Immunopathol 1986; 39:264-276.
  1. Kelley, VE, Farber, NM, Williams, JM, Strom, TB. Inability of autoimmune mice with the lpr gene to spontaneously produce interleukin-3.  Eur J Immunol  1986; 16:464-467.
  1. Hinglais N, Pelletier L, Vial MC, Sapin C, Bascov C, Bariety J, Kelley VE, Druet P. Effect of PGE1 in Brown-Norway rats with mercury-induced autoimmune disease.  Clin Immunol Immunopathol 1986; 40:401-409.
  1. Badr K, Kelley VE, Rennke H, Brenner B. Roles for thromboxane A2 and sulfidopeptide leukotrienes in endotoxin-induced acute renal failure.  Kidney Int 1986; 30:474-480.
  1. Noma T, Kelley VE, Kawasaki H, Minami M, Dorf ME. The differential ability of splenic adherent cells from B6-lpr mice to induce suppressor T cells.  J Immunol 1986; 136:3987-3993.
  1. Kelley VE, Strom TB. Spleen cell factor inhibits lymphoproliferation, abnormal Ia expression and overt auto-immunity in MRL-lpr mice. Clin Immunol Immunopathol 1986; 41:145-153.
  1. Kelley VE, Naor D, Tarcic N, Gaulton GN, Strom TB. Anti-interleukin-2 receptor antibody suppresses DTH.  J Immunol 1986; 137:2122-2124.
  1. Elzinga L, Kelley VE, Houghton DC, Bennett WM. Fish oil as the vehicle for cyclosporine modifies experimental nephrotoxicity.  Transplantation 1987; 43:271-273.
  1. Kelley VE, Gaulton G, Strom TB. Inhibitory effects of anti-interleukin-2 receptor and anti-L3T4 antibodies on delayed type hypersensitivity: The role of complement and epitope.  J Immunol 1987; 138:2771-2775.
  1. Kelly RA, O’Hara DS, Kelley V. Resolution by HPLC of femtomolar quantities of endogenous carboxylic acids, including arachidonic acid metabolites as 4-bromomethyl, 7-acetoxycoumarin derivatives.  J Chrom 1987; 416:247-254.
  1. Rogers TS, Elzinga L, Bennett WM, Kelley VE. Selective enhancement of thromboxane in macrophages and kidneys in cyclosporine A induced nephrotoxity.  Dietary protection by fish oil.  Transplantation 1988; 45:153-156.
  1. Kelley VE, Gaulton GN, Hattori M, Ikegami H, Eisenbarth G, Strom TB. Anti-interleukin-2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis.  J Immunol 1988; 140:59-61.
  1. Kelley VE, Bacha P, Pankewycz O, Nichols JC, Murphy JR, Strom TB. Interleukin-2 toxin fusion protein abolishes cell mediated immunity in vivo.  Proc Natl Acad Sci USA 1988; 85:3980-3984.
  1. Pankewycz O, Hassarjian R, Chang C, Strom TB, Kelley VE. Anti-interleukin-2 receptor monoclonal antibody induces anti-idiotypic antibodies in mice that block both in vitro and in vivo activity.  J Autoimmunity 1988; 1:119-130.
  1. Boswell JM, Yui MA, Burt DW, Kelley VE. Novel and enhanced interleukin-1 gene expression in autoimmune mice with lupus.  J Immunol 1988; 141:118-124.
  1. Boswell JM, Yui M, Burt DW, Kelley VE. Increased tumor necrosis factor and interleukin-1 beta gene expression in the kidneys of mice with lupus nephritis.  J Immunol 1988; 141:3050-3054.
  1. Issa-Chergui B, Guttmann RD, Seemayer TA, Kelley VE, Colle E. The effect of diet on the spontaneous insulin dependent diabetic syndrome in the rat.  Diabetic Res 1988; 9:81-86.
  1. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, Vander Meer J, Cannon JG, Rogers TS, Weber PC, Schaefer EJ, Wolff SM, Dinarello CA. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells.  N Eng J Med 1989; 320:265-271.
  1. Pankewycz O, Mackie J, Hassarjian R, Murphy JR, Strom TB, Kelley VE. Interleukin-2 diphtheria toxin fusion protein prolongs murine islet engraftment. Transplantation 1989; 47:318-322.
  1. Wuthrich RP, Yui MA, Mazoujian G, Nabavi N, Glimcher LH, Kelley VE. Enhanced MHC class II expression in renal proximal tubules preceeds loss of renal function in MRL-lpr mice with lupus nephritis. Am J Pathol 1989; 134:45-51.
  1. Kelley VE, Kirkman R, Bastos M, Barrett L, Strom TB. Enhancement of immunosuppression by substitution of fish oil for olive oil as a vehicle for cyclosporine.  Transplantation 1989; 48:98-102.
  1. Heagy W, Strom TB, Kelley VE, Collela J, Crumpacker C, William JM, Shapiro HM, Laubenstein L, Finberg R. Recombinant human gamma inteferon enhances in vitro activation of lymphocytes isolated from patients with acquired immunodeficiency syndrome.  Infec & Immun 1989; 57:3619-3628.
  1. Brennan DC, Wuthrich RP, Yui MA, Kelley VE. TNF and IL-1 in NZB/W mice: Enhanced gene expression and acceleration of renal injury.  J Immunol 1989; 143:3470-3475.
  1. Wuthrich, RP, Glimcher LH, Yui MA, Jevnikar AM, Dumas SE, Kelley VE. MHC class II expression, antigen presenting function and tumor necrosis factor expression by murine renal tubular epithelial cell lines. Kidney Int 1990; 37:783-792.
  1. Wuthrich RP, Jevnikar AM, Takei F, Glimcher LH, Kelley VE. Intercellular adhesion molecule-1 (ICAM-1) expression is upregulated in autoimmune murine lupus nephritis.  Am J Pathol 1990; 136:441-450.
  1. Pankewycz O, Yui MA, Kelley VE, Strom TB. The cascading interrelated roles of interleukin-1, interleukin-2 and interleukin-6 in murine anti-CD3 driven T cell proliferation.  Clin Immunol Immunopath 1990; 55:86-96.
  1. Mackie J, Pankewycz O, Bastos MG, Kelley VE, Strom TB. Dose related mechanisms of immunosuppresion mediated by murine anti-CD3 monoclonal antibody in pancreatic islet cell transplantation and delayed type hypersensitivity.  Transplantation 1990; 49:1150-1154.
  1. Lear S, Silva P, Kelley VE, Epstein FH. Prostaglandin E2 inhibits oxygen consumption in rabbit medullary thick ascending limb.  Am J Physiol 1990; 258:1372-1378.
  1. Jevnikar AM, Wuthrich RP, Takei F, Xu H, Brennan DC, Glimcher LH, Kelley VE. Differing regulation and function of ICAM-1 and class II antigens on renal tubular cells.  Kidney Int 1990; 38:417-425.
  1. Xu H, Jevnikar AM, Rubin-Kelley VE. A simple method for the preparation of chromosomal DNA from cell culture.  Nucl Acid Res 1990; 18:4943.
  1. Brennan DC, Jevnikar AM, Takei F, Rubin-Kelley VE. Mesangial cell accessory functions; mediation by intercellular adhesion molecule-1.  Kidney Int 1990; 38:1039-1046.
  1. Bastos MG, Pankewycz O, Rubin-Kelley VE, Murphy JR, Strom TB. Concomitant administration of hapten and IL-2 toxin (DAB486-IL-2) results in specific deletion of antigen activated T cell clones.  J Immunol 1990; 145:3535-3539.
  1. Pankewycz O, Strom TB, Rubin-Kelley VE. Islet infiltrating T cell clones from non-obese diabetic mice that promote or prevent accelerated onset of diabetes.  Eur J Immunol 1991; 21:873-879.
  1. Yui MA, Brisette WH, Brennan DC, Wuthrich RP, Rubin-Kelley VE. Increased macrophage colony-stimulating factor in neonatal and adult autoimmune MRL-lpr mice.   Am J Pathol 1991; 139:255-261.
  1. Jevnikar AM, Brennan DC, Singer GG, Heng JE, Maslinski W, Wuthrich RP, Glimcher LH, Rubin-Kelley VE. Stimulated kidney tubular epithelial cells express membrane associated and secreted TNF-.  Kidney Int 1991 ;40:203-211.
  1. Lakkis F, Steele A, Pacheco-Silva A, Rubin-Kelley V, Strom TB, Murphy JR. Interleukin-4 receptor targeted cytotoxicity: genetic construction and in vivo immunosuppressive activity of a diphtheria toxin-related murine interleukin-4 fusion protein.  Eur J Immunol 1991; 21:2253-2258.
  1. Pacheco-Silva A, Bastos MG, Muggia RA, Pankewycz O, Nichols J, Murphy JR, Strom TB, Rubin-Kelley VE. Interleukin-2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in NOD mice.  Eur J Immunol 1992; 22:697-702.
  1. Brennan DC, Jevnikar AM, Bloom RD, Brissette WH, Singer GG, Rubin Kelley V. Cultured mesangial cells from autoimmune MRL-lpr mice have decreased secreted and surface M-CSF despite increased circulating and renal expression.  Kidney Int 1992; 42:279-284.
  1. Díaz-Gallo C, Moscovitch-Lopatin M, Strom TB, Rubin-Kelley V. An anergic, islet-infiltrating T cell clone that suppresses murine diabetes secretes a factor that blocks Interluekin-2/Interleukin -4 dependent proliferation.  Proc Natl Acad Sci USA 1992; 89:8656-8660.
  1. Díaz-Gallo C, Jevnikar AM, Brennan DC, Florquin S, Pacheco-Silva A, Rubin Kelley V. Autoreactive kidney-infiltrating T-cell clones in murine lupus nephritis. Kidney Int 1992; 42:851-859.
  1. Jevnikar AM, Singer GG, Brennan DC, Xu H-W, Rubin-Kelley VE. Dexamethasone prevents autoimmune nephritis and reduces renal expression of Ia but not costimulatory signals.  Am J Pathol 1992; 141:743-751.
  1. Barel D, Brennan DC, Jevnikar AM, Bastos M, Strom TB, Rubin Kelley VE. Enhanced tumor necrosis factor in anti-CD3 antibody stimulated diabetic NOD mice: Modulation by PGE1 and dietary lipid.  Autoimmunity 1992; 13:141-149.
  1. Kreft B, Singer GG, Díaz-Gallo C, Rubin Kelley V. Detection of intracellular interleukin-10 by flow cytometry.  J Immunol Meth 1992; 156:125-128.
  1. O’Connell PJ, Pacheco-Silva A, Nickerson PW, Muggia RA, Bastos M, Rubin Kelley V, Strom TB. Unmodified pancreatic islet allograft rejection results in the preferential expression of certain T cell activation transcripts.  J Immunol 1993; 150:1093-1104.
  1. Bloom RD, Florquin S, Singer GG, Brennan DC, Rubin Kelley V. Colony stimulating factor-1 (CSF-1) in the induction of lupus nephritis. Kidney Int 1993; 43:1000-1009.
  1. Singer GG, Bloom RD, Jevnikar AM, Nabavi N, Rubin Kelley V. Stimulated renal tubular epithelial cells induce anergy in CD4+ T cells. Kidney Int 1993; 44: 1030-1035.
  1. Jevnikar AM, Singer GG, Coffman T, Glimcher LH, Rubin Kelley V. Renal tubular cell expression of MHC class II (I-Eb) is insufficient to initiate immune injury in a transgenic kidney transplant model. J Am Soc Nephrol 1993; 3:1973-1977.
  1. Díaz-Gallo C, Rubin Kelley V. Self-regulation of autoreactive T cells: Secretion of IFN-g by kidney-infiltrating T cell clones reduces the ability of renal tubular epithelial cells to promote proliferation. Kidney Int 1993; 44:1030-1035.
  1. Yokoyama H, Zheng X, Strom TB, Rubin Kelley V. B7+ transfectant tubular epithelial cells induce T cell anergy, ignorance or proliferation.  Kidney Int 1994; 45:1105-1112.
  1. Bennett WM, Carpenter CB, Shapiro ME, Strom TB, Hefty D, Tillman M, Abrams J, Ryan D, Rubin Kelley V. Delayed omega-3 fatty acid supplements in renal transplantation: A double-blind placebo-controlled study. Transplantation 1995; 59:352-356.
  1. Yokoyama H, Kreft B, Rubin Kelley V. Biphasic increase in circulating and renal TNF-a in MRL-lpr mice with differing regulatory mechanisms.  Kidney Int 1995; 47:122-130.
  1. Naito T, Griffiths RC, Coffman TM, Rubin Kelley V. A transplant approach establishes that the MRL-lpr kidney is responsible for persistent, circulating colony stimulating factor-1 (CSF-1); without the induction of CSF-1, nephritis resolves.  Kidney Int 1996; 49:67-74.
  1. Naito T, Yokoyama H, Moore KJ, Dranoff G, Mulligan RC, Kelley VR. Macrophage growth factors introduced into the kidney initiate renal injury.  Molecular Medicine 1996; 2:297-312.
  1. Kreft B, Yokoyama H, Naito T, Kelley VR. Upregulated transforming growth factor-ß in neonatal and adult autoimmune MRL-lpr mice. J Autoimmunity 1996; 9:463-472.
  1. Moore KJ, Yeh K, Naito T, Kelley VR. TNF-a enhances CSF-1 induced macrophage accumulation in autoimmune renal disease. J Immunol 1996; 157:427-432.
  1. Perkins DL, Listman JA, Marshak-Rothstein A, Kozlow W, Kelley VR, Finn PW, Rimm IJ. Restriction of the TCR repertoire inhibits the development of memory T cells and prevents autoimmunity in lpr mice. J Immunol 1996; 156:4961-4968.
  1. Moore KJ, Naito T, Martin C, Kelley VR. Enhanced response of macrophages to CSF-1 in autoimmune mice: A gene transfer strategy. J Immunol 1996; 157:433-440.
  1. Naito T, Yokayama H, Moore KJ, Dranoff G, Mulligan RC, Kelley VR. A gene transfer system establishes interleukin-6 neither promotes nor suppressses renal injury. Am J Physiol    1996; 271:40, F603-F609.
  1. Wada T, Naito T, Griffiths RC, Coffman TM, Kelley VR. Systemic autoimmune nephritogenic components induce CSF-1 and TNF-a in MRL mice. Kidney Int 1997;52,934-941.
  1. Moore KJ, Wada T., Barbee SD, Kelley VR. Gene transfer of RANTES elicits autoimmune

renal injury in MRL-Faslpr mice. Kidney Int 1998; 53, 1631-1641.

  1. Schwarting A, Wada T, Kinoshita K, Tesch G, Yoon H-J, Rubin Kelley VR. IFN-gR signaling is essential for the initiation, acceleration and destruction of autoimmune kidney disease in MRL-Faslpr mice. J Immunol 1998; 161:494-503.
  1. Schwarting A, Moore K, Wada T, Tesch G, Yoon H-J, Kelley VR. IFN-glimits macrophage expansion in MRL-Faslpr autoimmune interstitial nephritis: A negative regulatory pathway. J Immunol 1998; 160:4074-4081.
  1. Kim,YS, Maslinski W, Zheng XX, Stevens C, Li XC, Tesch GH, Kelley VR, Strom TB. Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity. J Immunol 1998; 160:5742-5748.
  1. Tesch GH, Schwarting A, Kinoshita K, Lan HY Rollins BJ, Kelley VR. Monocyte chemoattractant protein-1 promotes   macrophage-mediated  tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. J Clin Invest 1999; 103:73-80.
  1. Schwarting A, Tesch G. Kinoshita K, Maron R, Weiner HL, Kelley VR. IL-12 drives IFN-g dependent autoimmune kidney disease in MRL-Faslpr mice. J Immunol 1999; 163:6884-6891.
  1. Wada T, Schwarting A, Kinoshita K, Naito T, Griffiths R, Coffman R, Kelley VR. Fas on renal parenchymal cells does not promote autoimmune nephritis in MRL mice. Kidney Int 1999; 55:841-851.
  1. Tesch GH, Maifert S, Schwarting A, Rollins BJ, Kelley VR. Monocyte chemoattractant protein-1 dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Faslpr mice. J Exp Med 1999; 190:1813-1824.
  1. Kinoshita K, Tesch, G, Schwarting A, Maron R, Sharpe AH, Kelley VR. Costimulation by   B7-1 and B7-2 Is Required for Autoimmune Disease in MRL-Faslpr Mice.  J Immunol 2000; 164:6046-6056.
  1. Tu Z, Kelley VR, Collins T, Lee FS. IkB kinase is critical for TNF-a induced vascular cell adhesion molecule-1 gene expression in renal tubular epithelial cells. J. Immunol 2001; 166, 6839-6846
  1. Wada T, Schwarting A, Chestnutt MS, Wofsy D, Kelley VR. Nephritogenic cytokines and disease in MRL-Faslpr kidneys are dependent on multiple T cell subsets. Kidney Int 2001; 59:565-578
  1. Shinozaki M, Hirahashi J, Lebedeva T, Liew FY, Salant DJ, Maron R, Kelley VR. IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis. J. Clin Invest 2002; 109: 951-960
  1. Faust J, Menke J, Kriegsmann S, Kelley VR, Mayet WJ, Balle PR, Schwarting A. Upregulation of renal tubular epithelial cell derived interleukin 18 correlates with disease activity in autoimmune MRL-Faslpr lupus nephritis. Arthritis and Rheum 2002; 46:3083-3095 .
  1. Lenda DM, Kikawada E, Stanley ER, Kelley VR. CSF-1 dependent macrophage   proliferation, and activation results in tubular apoptosis during renal inflammation.  J Immunol 2003; 170:3254-3262.
  1. Kikawada E, Lenda DM, Kelley VR. IL-12 deficiency in MRL-Faslpr mice: Delays nephritis and intrarenal IFN-g production, and reduces systemic pathology. J Immunol 2003; 170:3915-3925.
  1. Lenda DM, Stanley ER, Kelley VR. Negative role of colony stimulating factor 1 in macrophage, T cell, and B cell mediated autoimmune MRL-Faslpr mice. J. Immunol 2004; 173:4744-4754.
  1. Duffield JS, Park KM, Hsiao L, Kelley VR, Scadden DT, Ichimura T, Bonventre JV. Restoration of tubular epithelial cells during repair of the post ischemic kidney is independent of bone marrow cells. J. Clin Invest 2005; 115:1743-1755.
  1. Schwarting A, Paul K, Tschirner S, Menke J, Hansen T, Brenner W, Kelley VR, Relle M, Galle PR. Interferon-beta suppresses autoimmune lupus. J Amer Soc Nephrol 2005; 16:3264-3272.
  1. Zeller GC, Hirahashi J, Schwarting A, Sharpe AH, Kelley VR. ICOS null MRL-Faslpr Mice: Uncoupling autoantibodies and lupus nephritis. J Amer Soc Nephrol 2006; 1:122-130.
  1. Jang W-H, Herber DM, Jiang X, Nandi S, Dai X-M, Zeller G, Stanley ER, Kelley VR. Distinct in vivo roles of colony stimulating factor-1 isoforms in renal inflammation. J. Immunol 2006; 177:4055-4063.
  1. Menke J, Lucas JA, Zeller GC, Keir ME, Huang XR, Tsuboi N, Mayadas TN, Lan HY, Sharpe AH, Kelley VR. PD-L1 and PD-L2 Limit Autoimmune Kidney Disease: Distinct Roles. J Immunol 2007; 179:7466-7477.
  1. Menke J, Zeller GC, Kikawada E, Means TK, Huang XR, Lan HY, Lu B, Farber J, Luster AD, Kelley VR. CXCL9, but not CXCL10, Promotes CXCR3 Dependent Immune Mediated Kidney Disease. J Amer Soc Nephrol 2008; 19:1177-1189.
  1. Lucas JA, Menke J, Rabacal WA, Schoen FJ, Sharpe AH, Kelley VR. Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL mice. J Immunol 2008;181:2513-2521.
  1. Menke J, Hsu M-Y, Byrne KT, Lucas JA, Rabacal WA, Croker B, Zong S-H, Stanley ER, Kelley VR. Sunlight Triggers Cutaneous Lupus through a Colony Stimulating Factor-1 (CSF-1) Dependent Mechanism. J Immunol 2008;181:7367-7389.
  1. Menke J, Iwata Y, Rabacal W, Basu R, Yeung YG, Humphreys BD, Wada T, Schwarting A, Stanley ER, Kelley VR. CSF-1 Signals Directly to Renal Tubular Epithelial Cells to Mediate Repair in Mice. J Clin Invest 2009;119:2330-2342.
  1. Menke J, Rabacal  WA, Byrne KT, Iwata Y, Schwartz  M, Stanley  ER, Schwarting  A, Kelley VR. Circulating and Systemic Colony Stimulating Factor-1 Increase Monocyte and Macrophage Phenotypes that Mediate Mouse Lupus Nephritis. J Amer Soc Nephrol 2009;12:2581-2592.
  1. Menke J, Bork T, Kutska B, Byrne KT, Blanfeld M, Relle M, Kelley VR, Schwarting A. Targeting Transcription Factor Stat4 uncovers a role for IL-18 in the pathogenesis of severe lupus nephritis in mice. Kid Inter 2011;4:452-463.
  1. Menke J, Iwata Y, Rabacal WA, Basu R, Stanley ER, Kelley VR. Differential Impact of Colony Stimulating Factor-1 Isoforms in Lupus Nephritis. J Amer Soc Nephrol 2011;22:1821-1833.
  1. Menke J, Kriegsmann J, Schimanski CC, Schwartz MM, Schwarting A, Kelley VR. Autocrine CSF-1 and CSF-1 Receptor Co-expression Promotes Renal Cell Carcinoma Growth. Cancer Res 2012: 72;1187-200.
  1. Iwata Y, Bostrom E, Menke J, Rabacal WA, Morel L, Wada T, Kelley VR. Aberrant Macrophages Mediate Defective Kidney Repair that Triggers Nephritis in Lupus-Susceptible Mice.” J Immunol. 2012:188; 4568-4581
  1. Menke J, Amann K, Cavagna L, Weinmann A, Schwarting A, Kelley VR. Colony Stimulating Factor 1: A Predictive Biomarker for Lupus Nephritis. J Amer Soc Nephrol 2015: 26; 364-378.
  1. Baek J-H, Zeng R, Weinmann-Menke J, Valerius MT, Ajay AK, Colonna M, Kelley VR. IL-34 Mediates Acute Kidney Injury and Worsens Subsequent Chronic Kidney Disease. J Clin Invest 2015: 125; 3198-3214.

Proceedings of Meetings

  1. Winkelstein A, Kelley VE, Silva RA. Effects of prostaglandin El (PGEl) on murine lymphocytes.  In: Kaplan JG, ed., Leukocyte Culture Conference. Amsterdam: Elsevier/North Holland Biomedical Press, 1979, 379-382.
  1. Izui S, Hara I, Kelley VE, Elder J, McConahey PJ, Dixon FJ. Retroviral gene expression and murine systemic lupus erythematosus.  In: Dixon FJ, Miescher PA, eds.  VII International Immunopathology Symposium. Orlando: Academic Press, 1982:263-283.
  1. Orlowska E, Maddock SM, Kelley VE, Fiers W, Strom TB.  Interleukin-2-stimulated changes in cellular metabolism precede de novo DNA synthesis.  Transplant Proc 1985;17:575-577.
  1. Kelley, VE. A role for thromboxane in immune mediated renal injury. Transplant Proc 1986;18:77-82.
  1. Kelley VE, Rogers TS, Elzinga L, Bennett WM. Fish oil protects from cyclosporine A induced nephrotoxity.  In: Sands WEM, ed., Proceedings of the AOCS Short Course on polyunsaturated fatty acids and eicosanoids.  Am Oil. Chemists Society of Champaign, IL, 1987:109-114.
  1. 6. Kelley VE, Strom TB. Immunosuppression by anti-interleukin-2 receptor antibody, but not anti-L3T4, requires terminal complement components. Transplant Proc. 1987;19:617.
  1. Kirkman RL, Barrett LV, Strom TB, Kelley VE. A fish oil vehicle increases the therapeutic index of cyclosporine.  Surg  Forum.  1987; 38:394-5.
  1. Kelley VE, Strom TB. Immunosuppression by anti-interleukin-2 receptor antibody, but not anti-L3T4, requires terminal complement components. Transplant Proc.  1987;19:617.
  1. Elzinga L, Kelley VE, Houghton DC, Bennett WM. Fish oil vehicle for cyclosporine lowers renal thromboxanes and reduces experimental nephrotoxicity. Transplant Proc 1987;19:1403-1406.
  1. Bennett WM, Elzinga L, Kelley VE. Pathophysiology of cyclosporine nephrotoxicity: Role of eicosanoids.  Transplant Proc 1988;20 (supp 13):628-633.
  1. Kelley VE, Murphy JR, Strom TB. Therapeutic strategies that target the interleukin-2 receptor.  In: Goetzl E, ed., UCLA Conference on Molecular and Cellular Mechanisms Human Hypersensitivity and Autoimmunity.  New York: Alan R. Liss, Inc., 1989:173-176.  (UCLA Symp. Molec. Cell Biol.-New Series; vol 105).
  1. Waters CA, Strom TB, Murphy JR, Kelley VE, Kirkman RL. Targeting the IL-2 receptor with IL-2 toxin: a novel immunotherapeutic.  In: Fradelizi D, Bertoglio J, eds.  Lymphocyte Receptor Interactions. Montrouge: Colloque INSERM/John Libbey Eurotext Ltd., 1989:179:163-170.
  1. Kelley VE, Bastos M, Bennett W, Strom TB. Fish oil:  Protects from cyclosporine induced nephrotoxicity and causes immunosuppression.  In: Leger CL, Bezerat G, eds. Biomembranes and Nutrition.  Paris: colloque Inserum, 1989;195:453-459.
  2. Mackie JD, Pankewycz OG, Hassarjian R, Murphy JR, Kelley VE, Strom TB.   Immunotherapy using interleukin-2 diphtheria toxin chimer prolongs murine allografts.  Transplant Proc.  1989; 21:2718-9.
  1. Kelley VE, Mackie J, Strom TB. Cyclosporin A plus fish oil; accentuate the positive, eliminate the negative. Transplant Proc 1989;21:848-849.
  1. Mackie JD, Pankewycz OG, Hassarjian R, Murphy JR, Kelley VE, Strom TB. Immunotherapy using interleukin-2 diphtheria toxin chimer prolongs murine allografts.  Transplant Proc 1989;21:2718-2719.
  1. Kelley VE, Murphy JR, Strom TB. Therapeutic strategies that target the interleukin-2 receptor. In: Goetzl E, ed. Proceedings UCLA Conference , Molecular and cellular mechanisms of human hypersensitivity and anti-immunity. New York: Alan R. Liss Inc; 1989, 105:pp.173-76.
  1. O’Connell PJ, Pacheco-Silva A, Bastos M, Xu HW, Pankewycz O, Rubin-Kelley VE, Strom TB.  Sequential analysis by polymerase chain reaction of mononuclear leukocyte activation-associated transcription in pancreatic islet cell allograft rejection.  Transplant Proc. 1991; 23:811-2.
  1. Jevnikar AM, Wuthrich RP, Brennan DC, Maslinski W, Glimcher LH, Rubin-Kelley VE. TNF-alpha is expressed on the surface of proximal tubular cells.  Transplant Proc 1991;23:231-232.
  1. Nickerson P, Pacheco-Silva A, O’Connell PJ, Steurer W, Kelley VR, Strom TB. Analysis of cytokine transcripts in pancreatic islet cell allografts during rejection and tolerance induction.  Transplant Proc. 1993; 25:984-5.
  1. Jevnikar AM, Singer GG, Coffman T, Glimcher LH, Rubin Kelley V. Renal tubular cell expression of MHC class II (I-Eb) is insufficient to initiate immune injury in a transgenic kidney transplant model.  Transplant Proc 1993;25:142-143.
  1. Nickerson P, Pacheco-Silva A, O’Connell PJ, Steurer W, Rubin Kelley V, Strom TB. Analysis of cytokine transcripts in pancreatic islet cell allografts during rejection and tolerance induction.  Transplant Proc 1993;25:984-985.
  1. Kelley VR, Strom TB. A paradigm 1994: The allograft response.  Blood Purification 1994; 8:1-6.

Reviews, Chapters and Editorials

  1. Cavallo T, Kelley VE. Protein transport in glomeruli with immune complexes.  In: Peeters H, ed. Peptides of Biological Fluids. Proceedings of the 26th Colloquium, Oxford: Pergamon Press; 1978; P.271-274.

 

  1. Winkelstein A, Kelley VE. Basic immunology for the family physician.    Family Practice Recertification,  Part I. Vol 1, No. 4, 1979; 58-68.

 

  1. Winkelstein A, Kelley VE. Basic immunology for the family physician.   Family Practice Recertification, Part II. Vol 1, No. 5, 1979; 53-63.

 

  1. Izui S, Kelley VE, McConahey PJ, Dixon FJ. Role of retroviral gp 70 immune complexes in the pathogenesis of  murine lupus nephritis.  In: Shiokawa Y, Abe T, Yamauchi Y, eds. New Horizons in Rheumatoid Arthritis. Amsterdam-Oxford-Princeton: Excerpta Medica, 1981: 96-101.

 

  1. Izui, S., I. Hara, V. E. Kelley, J. H. Elder, P. J. McConahey and F. J. Dixon. Retroviral gene expression and murine systemic lupus erythematosus. In: Dixon FJ and Miescher PA, eds Immunopathology. VIIIth International Symposium 1980, New York/London: Academic Press, 1982:P. 263-283.

 

  1. Izui S, Masuda K, Yoshida H, Kelley VE, Roths JB, Hara I. The lpr (lymphoproliferation) gene and retroviral gp 70 gene in murine lupus.  In:  Lambert P, Perrin L, Izui S, eds.  Recent advances in SLE.  Orlando: Academic Press; 1984: P. 45-61.

 

  1. Kelley VE. Cyclooxygenase metabolites and lupus nephritis.  In: Bertani T, Remuzzi G, Garattini S, eds.  Drugs and Kidney.  New York: Raven Press; 1986: P. 281-293.

 

  1. Strom TB, Gaulton GN, Kelley VE, Diamanstein T, Kupiec-Weglinski J, Tilney NL, Kirkman RL. Treatment with anti-interleukin-2 receptor monoclonal antibody.  In: Meryman HT, ed., Transplantation Approaches to Graft Rejection.  New York: Alan R. Liss Inc; 1986: P. 227-238.

 

  1. Strom TB, Gaulton GN, Kelley VE, Diamanstein T, Kupiec-Weglinski J, Tilney NL, Kirkman RL: Treatment with anti-interleukin-2 receptor monoclonal antibody. Prog Clin Biol Res 1986; 224:227-38.

 

  1. Kelley VE. Dietary effects on the progression of autoimmune glomerlonephritis.  In: Carpenter CB, ed., Clinics in Immunology and Allergy.  Philadelphia: W.B. Saunders; 1986: P.367-382.

 

  1. Strom TB, Gaulton GN, Kelley VE, Kirkman RL. Anti-interleukin-2 receptor monoclonal antibody treatment prolongs allograft survival.  In: Cinader B, Miller RB, eds.  Progress in Immunology VI.  Orlando: Academic Press Inc; 1986: P.909-914.

 

  1. Bennett WM, Elzinga L, Houghton D, Kelley V. Cyclosporine nephrotoxicity: Clinical and experimental aspects.  Nephrotoxity of antibiotics and Immunosuppressants.  In: Tanabe T, Hook JB, Endou,  eds.  Amsterdam:  Elsevier Scientific Publishers; 1986: P.123-128.

 

  1. Strom TB, Gaulton GN, Kelley VE, Diamanstein T, Kupiec-Weglinski JW, Tilney NL, Kirkman RL. Treatment of cardiac transplant recipients with anti-interleukin-2 receptor monoclonal antibody.  In Kawai C, Abelman WH, eds.  Cardiomyopathy.  Tokyo: University of Tokyo Press; 1987: P.173-179.

 

  1. Strom TB, Kelley VE, Murphy JR, Osawa H, Tilney NL, Shapiro ME, Kupiec-Weglinski JW, Diamanstein T, Gaulton GN, Kirkman RL. Interleukin receptor directed immunosuppressive therapy.  In: Webb DR, Pierce CW, Cohen S, eds.  Molecular Basis of Lymphokine Action. Clifton NJ: Humana Press: 1987: P. 371-389.

 

  1. Williams JM, Kelley VE, Kirkman NL, Tilney NL, Shapiro ME, Murphy JR, Strom TB. T cell activation antigens: therapeutic implications.  In:  Van Oss C, ed., Immunological Investigations.  New York: Marcel Dekker Inc; 1987: P. 687-723

 

  1. Strom TB, Kelley VE, Murphy JR, Osawa H, Tilney NL, Shapiro ME, Kupiec-Weglinski JW, Diamantstein T, Gaulton GN, Kirkman RL. Interleukin-2 receptor directed immunosuppressive therapy.  In: Smith, K. ed., A Volume of Lymphokines.  Orlando: Academic Press Inc; 1987: P. 223-236.

 

  1. Strom TB, Murphy JR, Williams D, Kelley VE. IL-2 toxin: A trojan horse strategy for controlling rejection.  In: Lipsky PE, Strom TB, eds.  Immunol and Allergy Clin. N. Am.  Philadelphia: W.B. Saunders Co; 1988: P. 69-78.

 

  1. Lear S, Kelley VE. Arachidonic acid metabolism in renal disease.  In: Halushka PV, Mais D, eds.  Eicosanoids in the Cardiovascular and Renal Systems.  Lancaster: MTP Press Ltd; 1988: P. 34-66.

 

  1. Murphy JR, Kelley VE, Strom TB. IL-2 toxin: A step toward selective immunomodulation.  Am J Kidney Dis 1988; 11:159-162.

 

  1. Strom TB, Murphy JR, Kelley VE. A trojan horse strategy for controlling rejection.  In:  Davison AM, ed., Proceedings of the Xth International Congress of Nephrology.  London: Bailliere Tindal; 1988: P. 1293-1299.

 

  1. Kelley VE, Pankewycz O, Murphy JR, Strom TB. Targeting chimeric interleukin-2 toxin to its receptor blocks delayed type hypersensitivity. In: Lipsky PF, Strom TB (eds) Therapeutic Advances in Clinical Immunology Immunology and Allergy Clinics N. Am; 1988: P. 129-130.

 

  1. Williams DP, Bacha P, Kelley, V, Strom TB, Murphy JR. Adenosine diphosphate ribosylation of elongation factor 2 as a therapeutic target.  Genetic construction and selective action of a diphtheria toxin-related interleukin-2 fusion protein.  In: Jacobson MK, Jacobson EL, eds.  ADP-ribose Transfer Reactions: Mechanisms and Biological Significance. Heidelberg: Springer Verlag; 1988: P. 478-486.

 

  1. Strom TB, Kelley VE, Murphy JR, Osawa H, Tilney NL, Shapiro ME, Kupiec-Weglinski JW, Diamantstein T, Gaulton GN, Kirkman RL. Interleukin-2 receptor directed immunosup- pressive therapy.  In: Webb DR, Pierce CW, Cohen S, eds.  Molecular Basis of Lymphokine Action, Clifton: Humana Press; 1988: P. 371-89.

 

  1. Waters CA, Strom TB, Murphy JR, Kelley VE, Kirkman RL. Targeting the IL-2 receptor with IL-2 toxin: a novel immunotherapeutic.  In: Fradelizi D, Bertoglio J, eds. Lymphokine receptor interaction, John Libbe Eurotext Ltd; 1989: P.163-70.

 

  1. Kelley VE, Bastos M, Bennett W, Strom TB. Fish oil: Protects from cyclosporine induced nephrotoxicity and causes immunosuppression. In: Leger  CL, Bereziat G, eds. Colloque Inserm Proc. Intl. Symp. Biomembranes and Nutrition.  1989; Vol.195, 453-60.

 

  1. Strom TB, Kelley VE. Toward more selective therapies to block autoimmunity.  In: Eisenbarth G, ed., Immunotherapy of Diabetes and Selective Autoimmune Diseases. Boca Raton: CRC Press Inc; 1989, P. 197-211.

 

  1. Strom TB, Kelley VE. Towards more selective therapies to block undesired immune responses.  Kidney Int 1989; 35:1026-1033.

 

  1. Strom TB, Murphy JR, Kelley VE. A trojan horse strategy for controlling unwanted immunologic activity.  In: Kaplan JG, Green DR, Bleackley CR, eds.  Cellular Basis of Immune Modulation. New York: Alan R. Liss Inc; 1989: P. 537-546.

 

  1. Kelley VE. The future of cytokines and anticytokines in the therapy of autoimmune diseases.  In: Bach FB, ed, Immunointervention in autoimmune diseases. Paris: Autoimmunity Forum, World Medical Communications Organization, 1989; 11-12.

 

  1. Pankewycz O, Strom TB, Kelley, VE. Therapeutic strategies using monoclonal antibodies in autoimmune disease.  In: Roitt IM, ed.  Current Opinion in Immunol, Philadelphia: Current Science, Ltd; 1989:1: P. 757-763.

 

  1. Strom TB, Anderson PL, Rubin-Kelley VE, Williams DP, Kiyokawa T, Murphy JR. Immunotoxins and cytokine toxin fusion proteins. Seminars in Immunology. 1990:2; 467-479.
  2. Bennett WM, Elzinga L, Winchester D, Kelley VE, Walker R, Whitworth JA. Modification of experimental cyclosporine nephrotoxicity and hypertension. In: Solez K, Racusen, eds.  Acute Renal Failure: Diagnosis, Treatment and Prevention.  New York: Marcel Dekker; 1991, P. 377-385.

 

  1. Rubin-Kelley VE, Jevnikar AM. Antigen presentation by renal tubular epithelial cells.  J Am Soc Nephrol 1991; 2:13-26.

 

  1. Strom TB, Anderson PL, Rubin-Kelley VE, Williams DP, Kiyokawa T, Murphy JR. Immunotoxins and cytokine toxin fusion protein.  In: Edelson RL, ed.  Antigen and clone-specific immunoregulation.  Annals of the NY Acad of Sci 1991; 636: 233-250.

 

  1. Strom TB, Kelley VR, Woodworth TG, Murphy JR. Interleukin-2 receptor-directed immunosuppressive therapies: antibody- or cytokine-based targeting molecules.  Immunological Reviews 1992; 129:131-163.

 

  1. Shapiro ME, Kirkman RL, Kelley VR, Bacha P, Nichols JC, Strom TB. In vivo studies with chimeric toxins.  Interleukin-2 fusion toxins as immunosuppressive agents. In:  Frankel AE ed. Genetically Engineered Toxins. New York: Marcel Dekker Inc; 1992, P. 383-93.

 

  1. Rubin Kelley V, Singer GG. The antigen presentation function of renal tubular epithelial cells.  Exp Nephr 1993;1:102-111.

 

  1. Rubin Kelley V, Díaz-Gallo C, Jevnikar AM, Singer GG. Renal tubular epithelial and T cell interactions in autoimmune renal disease.  Kidney Int 1993;43:S-108-115.

 

  1. Strom TB, Rubin Kelley V, Woodworth TG, Murphy JR. Interleukin-2 receptor directed immunosuppressive therapies: antibody or cytokine based targeting molecules.  In: Bach JF, ed.  Frontiers in Pharmacology and Therapeutics.  Oxford: Blackwell Scientific Publishers Ltd; 1993, P. 221-256.

 

  1. Strom TB, Rubin Kelley V, Murphy JR, Nichols J, Woodworth TG. Interleukin-2 receptor directed therapies: antibody or cytokine based targeting molecules.  In: Creger WP, Platt M, eds. Annual Review of Medicine; 1993,44:P. 343-353.

 

  1. Díaz-Gallo C, Rubin Kelley V. Clones isolated lymphocytes T in the experimental lupus nephritis manifested that the renal affectation of the systemic lupus erythematosus is organ-specific. Nefrologia (Spain) 1993;XIII (supplement):113-116.

 

  1. Díaz-Gallo C, Rubin Kelley V.T cell clones isolated in experimental lupus nephritis demonstate that renal injury in SLE is organ specific. Nefrología (Spain) 1993;13:113-116.

 

  1. Díaz-Gallo C, Rubin Kelley V. Activation of renal tubular cells diminishes autoimmune response in experimental lupus nephritis. Nefrología (Spain) 1993;13:106-108.

 

  1. Strom TB, Rubin Kelley V, Murphy JR, Nichols J, Woodworth TG. Thérapeutique dirigées contre le récepteur de l’interleukine-2: ultilisation des anticorps ou des cytokines. Flammarion Médicine-Sciences – Actualités Néphrologiques, 1993; 279-288.

 

  1. Strom TB, Rubin Kelley V, Murphy JR, Nichols J, Woodworth TG. IL-2R-directed therapies:  Antibody- or cytokine-based targeting molecules.  In: Creger WP, ed, Palo Alto: Annual Review  of Medicine;1993, 44:343-53.

 

  1. Strom TB, Rubin Kelley V, Murphy JR, Nichols J, Woodworth TG. Interleukin-2 receptor directed therapies: antibody-or cytokine-based targeting molecules.  In: Grunfeld JP, Bach JF, Kreis H, Maxwell MH. Advances in Nephrology, 1994; 23:347-356.

 

  1. Kelley, VR, Bloom RD, Yui MA, Martin C, Price D. Pivotal role of colony stimulating factor-1 in lupus nephritis. Kidney Int 1994; 45 (supplement) 1:83-85.

 

  1. Strom TB, Murphy JR, Woodworth TG, Kelley VR, Nichols J. IL-2 Receptor directed  therapies: Antibody or cytokine based targeting molecules.  In: Kupiec-Weglinski JW, Daniel F, Grosch S, ed. New Immunosuppressive Modalities and Anti-rejection Approaches in Organ Transplantation. Austin: Landes RG Co; 1994, P. 125-33.

 

  1. Yokayama H, Naito T, Dranoff G, Mulligan RC, Rubin-Kelley V. Gene transfer of macrophage growth factors into the kidney of lpr mice initiates renal injury. In: Koide H, Ichikawa I, eds. Progression of Chronic Renal Disease. Contrib Nephrol, Basel: Karger; 1996;118: P. 94-99.

 

  1. Wuthrich R, Kelley VR. Application of in situ hybridization to transplantation biology.  In: Paul PC, Strom TB, Tilney NL, eds. Transplantation Biology: Cellular and Molecular Aspects.  New York: Raven Press; 1996, P.107-111.

 

  1. Wuthrich R, Singer G, Kelley VR. Antigen presentation  in renal parenchyma. In: Neilson             EG, Couser WG, eds. Immunologic  Renal Disease.  New York: Raven Press; 1997, P. 193-      202.

 

  1. Kelley VR, Moore KJ. Applications of a gene transfer strategy to identify molecules that incite autoimmune kidney injury. Exp Nephrolol, 1997:5;144-151.

 

  1. Wuthrich R, Jevnikar A, Kelley VR. Understanding lupus nephritis. Unravelling the pathogenesis through molecular approaches in murine models. In : Lewis E, Schwartz MM, Korbet SM ed. Lupus Nephritis.  Oxford: Oxford University Press; 1999, P. 103-125.

 

  1. Kelley VR, Sukhatme V. Prospects for kidney gene transfer. Am J Physiol; 1999; 45:F1- F9.

 

  1. Yokayama H, Naito T, Wada T, Kelley VR. Application of genetically modified cells to

kidney disease: Engineering tubular epithelial cells. Exp Nephrol “Technical Seminars in

Nephrology” 1999; 7:267-272.

 

  1. Kelley VR,Wuthrich R. Cytokines in the pathogenesis of SLE. In: Kurtzman, N, ed.Seminars in Nephrology, Lupus Nephritis. Philadelphia: W.B. Saunders Co;1999;19, P. 57-66.

 

  1. Foster M, Kelley VR. Update on the pathogenesis of lupus nephritis. In: Kurtzman, N, ed. Seminars in Nephrology, Women in Nephrology. Philadelphia,W.B. Saunders Co.;1999;19:173-181.

 

  1. Tesch GH, Kelley VR. Chemokines as therapeutic targets in renal inflammation. Authors Reply. Am J Kid Dis 1999; 34:765-767.

 

  1. Kelley VR, Wuthrich R. Antigen presentation in renal parenchyma. In: Neilson EG, Couser   WG, eds. Immunologic Renal Disease.  New York: Lippincott Williams & Wilkins; 2001, P. 195-205.

 

  1. Kelley VR, Rovin BH. Chemokines : Therapeutic targets for autoimmune and inflammatory kidney disease.  In: Kelly, C, ed. Springer Seminars in Immunopathology. Heidelberg: Springer-Verlag; 2003, P.411-421.

 

  1. Kelley VR. Epithelial cell and macrophage interactions that regulate lupus nephritis. In: Kelley VR guest ed, Seminars in Nephrology, Philadelphia: W.B. Saunders Co; 2007:27; 59-68.

 

  1. 62. Kelley VR, Morel L, Foster MH. The genetics and pathogenesis of lupus. In: Mount D and Pollak M, eds. Molecular  and Genetic Basis of Renal Disease: A Companion to the Brenner and Rector’s The Kidney. Philadelphia: Elsevier Health Sciences; 2008: 509-530.

 

Back To Top